Replies to post #754225 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

Just my take. When Flaskworks is approved sometime in the future (don’t know when), you won’t need as many highly educated people to oversee DCVax-l manufacturing. Those highly educated people are still really valuable for Advent to retain, and their pathway to non-NWBO-dilutive locations, is important. JMHO.

Do you think NWBO will get a refund from Advent after Flaskworks is approved and the highly educated people to oversee DCVax-l manufacturing and the infrastructure that NWBO paid for are no longer needed? Or will Toucan only send a thank you for your huge investment in Advent without much reciprocity Xmas card?

[XMaster2023]

After DCVax-L & Flaskworks are approved, the demand for off label treatment of other cancers will skyrocket. Those highly trained people will be SWAMPED. Then The manufacturers will need that 200,000 SF facility. Somewhere. That is why NWBO and Advent are separate. CRL will be able to handle Manufacturing by then and the processes will be well defined.